Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors
Authors
Plummer, RSanborn, R
de Vries, E
Lorusso, P
Arkenau, H
Uboha, N
Wydmanski, J
Fidler, M
Boni, V
Garcia-Corbacho, J
Humphrey, R
Will, M
Autio, K
El-Khoueiry, A
van Oordt, C
Thistlethwaite, Fiona C
Affiliation
Northern Institute for Cancer Research, Newcastle University, Newcastle Upon TyneIssue Date
2018
Metadata
Show full item recordCitation
Plummer R, Sanborn RE, de Vries EGE, Lorusso P, Arkenau HT, Uboha N, et al. 436P Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors. Ann Oncol. 2018;29(suppl_8):143.Journal
Annals of OncologyDOI
10.1093/annonc/mdy279.423Additional Links
https://dx.doi.org/10.1093/annonc/mdy279.423Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy279.423